Please assess the completion status of the following clinical trial:

Trial Title: Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* healthy volunteers~* BMI between 18.5 and 29.9 kg/m2~* weighing between 55 and 95 kg~* willing to use reliable contraception~* able to give fully informed written consent.~Exclusion Criteria:~* Pregnant or lactating woman, or sexually active woman of child-bearing potential not using highly effective contraception~* clinically relevant abnormal medical history, surgery or concurrent medical condition; acute or chronic illness~* clinically significant QT/QTc interval prolongation at Baseline~* history of drug-induced or risk factors for Torsade de Pointes~* any contraindication to moxifloxacin~* severe adverse reaction to any drug or sensitivity to the trial medication or its components~* significant food allergy; use of vitamins, herbal medicines, prescription or over-the-counter medication (with the exception of paracetamol \[acetaminophen\] and oral contraceptives for women) within 20 days or 6 half-lives before first dose of trial medication~* participation in other clinical trials of unlicensed or prescription medicines, or loss of more than 400 mL blood, within the 3 months before first dose of trial medication~* drug or alcohol abuse; smoking of more than 5 cigarettes, 1 cigars or 1 pipes daily~* regular consumption of more than 5 cups of caffeinated drinks per day~* positive test for hepatitis A, B \& C, HIV~* objection by a General Practitioner.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Imeglimin therapeutic dose (Type: EXPERIMENTAL): Tablet, oral, single dose
- Imeglimin supratherapeutic dose (Type: EXPERIMENTAL): Tablet, oral, single dose
- Placebo (Type: PLACEBO_COMPARATOR): Tablet, oral, single dose
- Moxifloxacin (Type: ACTIVE_COMPARATOR): Tablet, oral, single dose (400 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).